Table 1.
Treatment | N | Timing | Heart rate (beats/min) |
RR (ms) | PR (ms) | QRS (ms) | QT (ms) |
---|---|---|---|---|---|---|---|
Pilocarpine | 5 | Before | 673.8±15.21 | 89.04±2.13 | 29.58±0.26 | 8.64±0.46 | 19.63±1.17 |
5 | After | 552.7±12.84*# | 108.55±2.96*# | 31.85±0.55*# | 9.49±0.53 | 19.88±1.18 | |
Saline | 5 | Before | 687.6±13.85 | 87.26±2.02 | 30.31±0.44 | 7.43±0.32 | 19.89±1.19 |
5 | After | 684.5±11.98 | 87.66±1.92 | 29.71±0.97 | 7.53±0.60 | 19.52±0.92 | |
Methoctramine | 5 | Before | 672.0±14.67 | 89.28±2.09 | 29.54±0.65 | 8.61±0.29 | 19.40±0.59 |
5 | After | 743.6±17.45*# | 80.69±1.81*# | 28.67±0.40*# | 7.89±0.31 | 19.08±0.66 |
ECG tracings were analyzed from mice treated with muscarinic modulators for 24 hours for modifications of electrical movement during muscarinic receptor manipulation. RR, PR, QRS, and QT indicate the R-R interval, the P-R interval, the QRS complex, and the QT interval, respectively.
: p<0.05 vs. respective saline after treatment;
: p<0.05 vs. the same group before treatment.